MedTrace Logo

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

NCT00679627 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2051

Last updated 2013-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).

Conditions

Interventions

DRUG

Galantamine

8mg/ day oral capsule increased to 16mg/day then to 24 mg per day

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC C. Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • Czechia
  • Estonia
  • France
  • Germany
  • Greece
  • Latvia
  • Lithuania
  • Romania
  • Russia
  • Slovakia
  • Slovenia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679627 on ClinicalTrials.gov